Currently, the hypothesis supporting the former conclusion posits that SGLT2 inhibitors might promote the growth of malignant cells through persistent glycosuria or chronically irritate the bladder epithelium through recurrent urinary tract infections, thereby increasing the risk of bladder cancer (26). Here, SLC5A2 is linked to urinary bladder carcinoma.